Sign In
Linkedin Youtube
EN ES

Publications

Publication Type
Keywords
Publication Year

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Article
Author:
Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, ByakhovMJ, Lichinister M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J
Parent Trial:

NOAH

Randomized comparison of adjuvant treatment with aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): joint analysis of IBCSG text and SOFT trials

Congress Communications
Author:
Pagani O, Regan MM, Walley B, Fleming GF, Colleoni M, Lang I, Leonidas Gomez H, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer Jr. CE, Rabaglio-Poretti M, Coates AS, Gelber RD, Goldhirsch A, Francis PA, SOFT and TEXT Investigators and International Breast Cancer Study Group
Parent Trial:

SOFT

CO-SOFT: the cognitive function substudy of the suppression of ovarian function trial (SOFT)

Congress Communications
Author:
Phillips K-A, Feng Y, Ribi K, Bernhard J, Puglisi F, Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Regan MM, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Fleming GF, Francis PA.
Parent Trial:

SOFT

Estrogen levels during first 12 months in premenopausal (PREM) patients (PTS) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant treatment with triptorelin (TRIP) plus tamoxifen (T) or exemestane (E) in the SOFT trial: SOFT-EST substudy

Congress Communications
Author:
Bellet M, Gray KP, Francis PA, Lang I, Ciruelos E, Lluch A, Climent MA, Catalan G, Ferrer Costa R, Catalan R, Rajasekaran A, Morales J, Vazquez J, Fleming GF, Price KN, Regan MM, SOFT-EST Investigators, SOLTI and International Breast Cancer Study Group
Parent Trial:

SOFT-EST (SOFT substudy)

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the retreatment after herceptin adjuvant trial.

Article
Author:
Láng I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J
Parent Trial:

WO17299

PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIa HER2-positive breast cancer

Congress Communications
Author:
Vidal M, de La Pena L, Oliveira M, Cortes J, Llombart A, Prat A, SOLTI Breast Cancer Research Group.
Parent Trial:

PAMELA

PAM50 HERr2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIa HER2-positive breast cancer

Congress Communications
Author:
Vidal M, de la Peña L, Oliveira M, Cortes J, Llombart A, and Prat A.
Parent Trial:

PAMELA

Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant andPIK3CA wild-type primary breast cancer – NeoPHOEBE.

Congress Communications
Author:
Loi S, Loibl S, Di Cosimo S, Nekljudova V, Flamen P, Saini KS, Michiels S, de la Pena L, Nanni S, Urban P, Piccart M, von Minckwitz G, Baselga J.
Parent Trial:

NeoPHOEBE (BIG 6-11 / GBG 73)

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience

Article
Author:
Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Van Dooren V, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M
Parent Trial:

ALTTO (BIG 2-06/N063D)

APHINITY (BIG4-11/BO25126/TOC4939G/GEICAM2010-11/SOLTI1006) Estudio fase III, randomizado, doble ciego, controlado con placebo que compara QT + trastuzumab + placebo vs QT + trastuzumab + pertuzumab, como tratamiento adyuvante en pacientes con cáncer de mama operable HER2+

Congress Communications
Author:
Manuel Ruiz-Borrego; José Manuel Pérez; Isabel Calvo; Amparo Ruiz; Juan de la Haba; Eva Ciruelos; Sonia Pernas; Eduardo Martínez; Noelia Martínez; Antonio Antón. Miembros del Grupo GEICAM y del Grupo SOLTI.
Parent Trial:

APHINITY (BIG 04-11/ BO25126/ TOC4939G)
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  
X

En Grupo Solti utilizamos cookies, propias y de terceros, analíticas, publicitarias y de elaboración de perfiles, basadas en hábitos de navegación del usuario, para mejorar la calidad del servicio, medir la audiencia y ofrecerle publicidad que pueda ser de su interés. Puede obtener más información en nuestra Política de Cookies.

Entendemos que acepta el uso de cookies en caso de que siga navegando.

Puede gestionar las cookies y aceptarlas o rechazarlas en el Panel de Configuración.